Payden & Rygel
- SEC CIK
- 0000919219
- Latest filing
- Jul 31, 2026
ABT holding history
Abbott Laboratories in every 13F filed by Payden & Rygel, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
ABT overviewAll 13F holders of ABTFull Q2 2026 holdings
- Shares (Q2 2024)
- 0
- Sold out in Q2 2024
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 13
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2024 | 0 | $0 | 0.0% | −133,500−100.0% | Sold out | Holders |
| Q1 2024 | 133,500 | $15.2M | 1.0% | −30,990−18.8% | Reduced | Holders |
| Q4 2023 | 164,490 | $18.1M | 1.3% | +51,900+46.1% | Added | Holders |
| Q3 2023 | 112,590 | $10.9M | 0.9% | −98,300−46.6% | Reduced | Holders |
| Q2 2023 | 210,890 | $23.0M | 1.6% | −11,400−5.1% | Reduced | Holders |
| Q1 2023 | 222,290 | $22.5M | 1.3% | +110,060+98.1% | Added | Holders |
| Q4 2022 | 112,230 | $12.3M | 0.7% | −89,300−44.3% | Reduced | Holders |
| Q3 2022 | 201,530 | $19.5M | 1.1% | +8,900+4.6% | Added | Holders |
| Q2 2022 | 192,630 | $20.9M | 1.3% | 00.0% | Unchanged | Holders |
| Q1 2022 | 192,630 | $22.8M | 1.2% | −87,100−31.1% | Reduced | Holders |
| Q4 2021 | 279,730 | $39.4M | 1.8% | −900−0.3% | Reduced | Holders |
| Q3 2021 | 280,630 | $33.2M | 1.7% | 00.0% | Unchanged | Holders |
| Q2 2021 | 280,630 | $32.5M | 1.6% | +261,900+1,398.3% | Added | Holders |
| Q1 2021 | 18,730 | $2.25M | 0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.